Posts

Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback

on

FDA Rejection Derails PTC Therapeutics' Rare Disease Hopeful

on

iTeos to Shut Down Operations After TIGIT Therapy Setback

on

J&J's $130M gene therapy bet flunks rare retinal disease trial

on

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

on

Back to the drawing board for Vertex's 'cells plus device' diabetes programme

on

Cassava Sciences Discontinues Alzheimer's Program After Simufilam Fails Second Phase 3 Trial

on

Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial

on

Supernus Pharmaceuticals' Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial

on

Supernus Pharmaceuticals' Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint

on

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

on

Sanofi and Johnson & Johnson's E. coli Vaccine Candidate Fails in Phase 3 Trial

on

Bristol Myers Squibb's Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

on

Roivant's Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

on

Sanofi's E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge

on

Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures

on